Universal Access and Affordable Medicines

Our campaign promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.

About our work on access to medicines

Watch now

Publications

See all

Latest Developments

New civil society roadmap to improve treatment of children and rare diseases

May 21, 2021

Recommendations for the revision of EU legislation on medicines for childhood and rare diseases from EPHA, ECL, SIOPE and the European Fair Pricing Network

HERA should be independent and autonomous with a clear public health mission, EPHA says

Feb 24, 2021

HERA should be independent and autonomous with a clear public health mission, EPHA says in its response to the European Commission’s consultation

Increasing our options for cancer treatment in Europe

Feb 10, 2021

EPHA member, the Anticancer Fund calls for more research into repurposing of drugs to support cancer patients

See all

Analysis & Opinion

Europe’s Beating Cancer Plan: Let’s focus on treatments that bring the most value to patients

Mar 30, 2021

Patients must be put at the heart of treatments developed as part of Europe’s Beating Cancer Plan

Best treatment for cancer patients in Europe?

Nov 14, 2020

If the EU wants to ensure “access to the best treatment for all” in its “Europe’s Beating Cancer plan” what changes need to be made to the assessment process for new cancer treatments?

The European Pharmaceutical Strategy: An inventory for action for Europe

Nov 14, 2020

What could we hope for from the upcoming EU Pharmaceutical Strategy, expected on 24 November

See all

Events

EPHA #A2MDialogues

A new series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.

Find out more and register for the latest discussion below

The Oslo Medicines Initiative: a new social contract with pharma

15 June 2021 | 13:00-14:00 CEST

A discussion with the WHO Regional Office for Europe and the Norwegian Medicines Agency about their new initiative to rebalance the relationship between governments, pharma and patients

Register now